SEC Filing · FWP
Nuvation Bio Inc.
NUVBNYSEEQUITYCurrent
SEC Filing
Company context
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Current securities
As-filed source
As filedOpen full document ↗